CD8+ and DUSP4hi CD4+ T cells additionally had increased interferon and TCR signaling pre-treatment (Figures S5C and S5D), indicating that at least a fraction of those cells may be tumor-reactive, corroborating our findings in Figure 3G. All four effector T cell subsets shared pathways related to TCR signaling in the top 50 of upregulated pathways pre-treatment (Figure S4E). The gene discussed is CD8A; the disease is neoplasm.